Rinvoq ER 30 MG tablet UU 30S
Ended Awarded Last action
- Contract number
- SPE2DR26F96Z8
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $13,248
Award facts
- Contract value 100% obligated
- $13,248.22 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $13,248.22 to AmerisourceBergen Drug Corp for the supply of RINVOQ ER 30 mg tablets (30-count unit dose packaging) with an ultimate completion date of January 15, 2026. This competitively awarded, firm fixed-price contract includes no set-aside designation and will be performed at the awardee's facility in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a selective JAK inhibitor used in the treatment of rheumatoid arthritis and other inflammatory conditions, representing the type of specialized pharmaceutical commodity the Defense Logistics Agency procures to support military and veteran healthcare systems.
This delivery order is issued under AmerisourceBergen Drug Corp's parent company Cencora, Inc.'s significant Indefinite Delivery Contract with the Defense Logistics Agency Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2031. This single-award IDC serves as the comprehensive vehicle for delivering pharmaceutical products and medical supplies to support military healthcare programs globally, including specialty medications, brand-name and generic drugs, vaccines, and related medical commodities. The structure enables efficient fulfillment of government requirements for essential medications across multiple therapeutic domains required by military treatment facilities and veterans' healthcare programs.
Quick answers
Who was awarded contract SPE2DR26F96Z8?
SPE2DR26F96Z8 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 14, 2026.
How much is contract SPE2DR26F96Z8 worth?
The government has obligated $13,248 on SPE2DR26F96Z8.
Is contract SPE2DR26F96Z8 an order under another contract?
Yes. SPE2DR26F96Z8 is a delivery order under SPE2DR25D3505, an indefinite delivery contract.
Was contract SPE2DR26F96Z8 competed?
The extent of competition for SPE2DR26F96Z8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award